source
- ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You GoBreast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.onclive · 3mo ago↗ source
- Disease Assessment and Mutational Testing in Progressive CLLExperts discuss relapsed CLL workup, using PET-CT and lymph node biopsy to rule out Richter’s, plus resistance testing to guide next therapy.onclive · 3mo ago↗ source
- Clinical Scenario Presentation and Treatment Approach for Progressive DiseaseExperts weigh mutation testing, comorbidities, and patient preference to guide second-line CLL options after BTK inhibitor resistance.onclive · 3mo ago↗ source